Efficacy of neuroprotective treatment including pyrimidine nucleotides in secondary uveitic glaucoma
Journal Title: Офтальмологический журнал - Year 2018, Vol 0, Issue 2
Abstract
Background: Secondary glaucoma is found in 18% to 38% of patients with uveitis, and is one of the most severe uveitic complications. The glaucomatous process is characterized by the progressive optic nerve neuropathy. The lack of efficacy of conventional neuroprotective approaches urged us to search for novel medications capable of stabilizing glaucoma. Purpose: To investigate the efficacy of neuroprotective treatment with pyrimidine nucleotides for secondary uveitic glaucoma. Materials and Methods: Patients with secondary uveitic glaucoma were divided into the study group (23 patients; 23 eyes) and the control group (21 patients; 21 eyes). The multicomponent neuroprotective treatment of the study group (but not of the control group) included a direct neuroprotector, Nucleo CMP Forte® drug containing two pyrimidine nucleotides, cytidine 5'-monophosphate and uridine 5'- triphosphate. The group received 2 ml of the drug intramuscularly daily for 10 days, and, thereafter, 2 capsules orally twice daily for 20 days. Each patient underwent visual acuity measurement and perimetry. In addition, phosphene threshold current (PTC) and critical frequency of phosphene (CFP) were determined. Results: Although no improvements in functional characteristics of the visual system were observed in the control group, the use of the pyrimidine nucleotide-containing drug as a component of therapy for uveitic glaucoma contributed to a 39% improvement in visual acuity, 17% increase in total visual field, 22% decrease in PTC, and 23% increase in CFP compared with baseline. Our long-term findings evidence that glaucoma was stabilized with neuroprotective therapy including, in particular, Nucleo CMP Forte, with generally maintained peripapillary RNFL thickness. Conclusion: The use of the pyrimidine nucleotide-containing drug as a component of therapy for uveitic glaucoma promoted an improvement in visual function and contributed to stabilization of glaucoma over 6-8 months
Authors and Affiliations
V. Savko Snr
Keywords
Related Articles
- EP ID EP422113
- DOI 10.31288/oftalmolzh/2018/2/2933
- Views 90
- Downloads 0
Mobility of oculomotor system and lability of visual analyzer in patients with primary open-angle glaucoma
Purpose: to perform a comparative assessment of oculomotor system mobility and visual system lability in patients with primary open-angle glaucoma (POAG) of stages II and III with compensated IOP. Material and Methods:...
Value of neurohumoral dysfunction in the pathogenesis of traumatic optic neuropathy
Background: It is not known in which way neurohumoral properties of the hypothalamus undergo changes due to traumatic optic nerve neuropathy (TON). Purpose: To investigate the value of neurohumoral dysfunction in the pa...
Effect of tear substitutes with various sodium hyaluronate levels on the condition of eye anterior segment in dry eye syndrome patients
The purpose of the present paper was to compare the effect of tear substitutes with various sodium hyaluronate levels (0.21% and 0.4%) on eye anterior segment condition and to determine the informative value of various d...
Features of the application of neuroprotective therapy for traumatic optic neuropathy in the clinical setting
Background: The features of the application of neuroprotective therapy for traumatic optic neuropathy (TON) in the clinical setting are not known. Methods: Forty-nine TON patients (49 eyes) with MRI evidence of no compr...
Our current understanding of metastasis and the potential for predicting the course of head and neck squamous cell carcinoma
This review presents recent studies on the mechanisms of malignant neoplasm metastases, particularly, in head and neck squamous cell carcinoma (HNSCC). The involvement of circulating tumor cells (CTC) and cancer stem cel...